CANCER PHARMACOLOGY CORE

癌症药理学核心

基本信息

批准号：
8288343
负责人：
Charles Leslie Hoppel
金额：
$ 14.29万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至 2013-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8288343
关键词：
Antineoplastic Agents Atmospheric Pressure Behavior Biological Assay Cancer Center Cancer Center Support Grant Cancer Therapy Evaluation Program Categories Clinical Research Clinical Trials Comprehensive Cancer Center Core Facility Databases Development Developmental Therapeutics Program Drug Design Drug Formulations Drug Kinetics Elements Funding Grant Laboratories Letters Methodology Methods Mission Molecular Weight O(6)-benzylguanine Optics Pharmaceutical Preparations Pharmacology Phase Rebeccamycin Analogue Recommendation Research Design Research Personnel Sampling Schedule Thalidomide Therapeutic Therapeutic Agents Translational Research United States National Institutes of Health Work analytical method base cancer pharmacology cancer therapy chemotherapeutic agent design detector docetaxel dosage instrument ionization mass spectrometer method development methoxyamine novel operation phthalocyanine Pc 4 programs sample collection silicon phthalocyanine small molecule symposium

项目摘要

The Cancer Pharmacology Core Facility (CPCF) provides an analytical laboratory for accurate and sensitive chromatographic determination of chemotherapeutic drugs and some drug metabolites. The facility staff provides the expertise necessary for development of thoroughly validated drug determination methods. The staff also participates in the design of clinical studies of chemotherapeutic agents by specification of sample collection methodology and recommendation of sampling intervals on the basis of expected pharmacokinetic behavior of studied therapeutic agents. The facility determines drugs in dosage formulations as an element of study design in most of the clinical trials in which we participate. The CPCF has an atmospheric pressure ionization triple quadrupole mass spectrometer (API/MS) which was purchased with NIH BRS shared instrument program grant funds. This instrument is very selective and sensitive toward certain categories of small molecules which include many cancer treatment drugs of low molecular weight. This instrument enables us to bring analytical methods into operation sooner than is possible with optical chromatographic detectors. The availability of this instrument within the CPCF has enabled the Cancer Center to attract funding for clinical trials of thalidomide in combination with docetaxel, and OSI-774 in combination with docetaxel. The facility maintains a database of these analytical results, and it conducts pharmacokinetics analysis of those results.

癌症药理学核心设施（CPCF）提供了一个分析实验室，可准确敏感化学治疗药物和某些药物代谢产物的色谱测定。设施人员提供开发彻底验证的药物确定方法所需的专业知识。这员工还通过样本的规范参与化学治疗剂的临床研究设计根据预期的药代动力学的收集方法和建议间隔的建议研究剂的行为。该设施确定剂量制剂中的药物为元素在我们参与的大多数临床试验中，研究设计。 CPCF具有大气压力电离三杆质谱仪（API/MS）使用NIH BRS共享仪器计划赠款资金购买。该乐器非常有选择性，并且对某些类别的小分子敏感，包括许多低癌症治疗药物分子量。该仪器使我们能够比IS更快地进行分析方法使用光学色谱检测器可能。 CPCF中此乐器的可用性使癌症中心能够吸引用于与多西他赛结合的沙利度胺临床试验的资金，和OSI-774与多西他赛结合使用。该设施维护了这些分析结果的数据库，并且它对这些结果进行药代动力学分析。